|
|
|
|
Search Skin & Aging
|
|
|
|
|
Eczema
Skin and Aging is the most comphrehensive resource on the web regarding the subject of Eczema and how it affects dermatology professionals. Feel free to browse through our articles below. |
|
Managing Hyperkeratotic Eczema of the Hands and Feet
An overview of the role of systemic retinoid therapy in treating this condition.
|
ATOPIC DERMATITIS Update
Highlights of recent news and trends.
|
News & Trends
News & Trends News and Trends: News & Trends - FDA Approvals & News New Dermal Filler Approved The FDA has approved a new dermal filler that is a hyaluronic acid filler that is non-animal stabilized. New Educational Program for Eczema Patients and Caregivers Novartis Pharmaceuticals Corporation launched Treat Eczema Now, a nationwide public education initiative designed to help patients and physicians overcome barriers to effective long-term control of eczema. Through the Treat Eczema Now ...
|
Immunomodulators in Action
A year has passed since the first topical immunomodulator was approved ? and a second is making its debut. Here, learn how leading doctors are using this new class of drugs to treat atopic dermatitis.
|
Infectious Complications of Atopic Dermatitis
Infectious Complications of Atopic Dermatitis Pediatric Patient Care: Infectious Complications of Atopic Dermatitis - By Irene Lara, M.D., and Miriam Weinstein, M.D., F.R.C.P.C. Atopic dermatitis is one of the most common dermatoses presenting to pediatric dermatologists. Staphylococcus aureus re-colonization in atopic dermatitis: beyond the skin. Clinical & Experimental Dermatology 2005; 30: 10.22 Benenson S, Zimhony, O, Dhan, D. Atopic dermatitis — a ...
|
News & Trends
News & Trends News and Trends: News & Trends - FDA Approvals & NewsOlux-E Approved to Treat Psoriasis and EczemaBaselineWeek 2FDA granted approval for clobetasol propionate (Olux-E Foam, 0.05%) for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive psoriasis and eczema in patients aged 12 years and older. During the studies, 251 people were treated twice daily for 2 weeks with Olux-E Foam and 126 subjects were treated with vehicle foam. At the end of ...
|
Atopic Dermatitis Update
Highlights of news, trends and research. Plus, experts discuss the impact the black box warnings on TCIs have had on some dermatologists? prescribing habits.
|
S&A News & Trends
S&A News & Trends News and Trends: S&A News & Trends - FDA Approvals & News First-of-Its-Kind Acne TreatmentThe U.S. Food and Drug Administration (FDA) has approved the first combination product of its kind for treating acne. Drug for Cutaneous T-Cell Lymphoma Approved The FDA has approved Merck’s vorinostat (Zolinza) as an orphan drug for the treatment of advanced cases of cutaneous T-cell lymphoma (CTCL). The results of this study were as follows:• Overall objective ...
|
News and Trends
Onychomycosis Therapy New Survey Documents Patient Satisfaction Results Onychomycosis can be a chronic condition for our patients ? Manjula Jegasothy, M.D. web review Hormone Replacement Therapy Use May Prevent Leg Ulcers in Older Women Researchers may have discovered a preventive therapy in treating pressure ulcers and venous leg ulcers in women older than 65 years. In a related study, patients treated with Luxiq for scalp dermatoses noted an improved quality of life over other patients ...
|
Managing Eczematous Dermatitis
The impact of appropriate skin care.
|
|
 |
|
|
|
| Search Skin & Aging ArticlesAcne Article |
Our extensive catalog of Skin & Aging journal articles is right at your fingertips!
|
|
|
|
| Skin & Aging Supplements |
Not Just Skin Deep: New Concepts & Approaches to Acne & "Actinic Keratosis"
This Supplement includes the proceedings from a Johns Hopkins CME Symposium
|
 THE MANY FACES OF ROSACEA
Topical Treatment of Rosacea: A Clinical Update
One out of every 22 people in the United States has
rosacea, a chronic, progressive, inflammatory skin
condition that causes a variety of facial cutaneous
and ocular symptoms. Although rosacea predominantly
affects adults between the ages of 30 and 50 years, 3 clinicians
routinely treat patients with rosacea well into their 60s, 70s
and even 80s.
Download PDF |
 CME Critical Reviews of Clinical Data:
Focus on Anti-TNF Agents
for the Treatment of Psoriasis
Psoriasis is one of several systemic diseases presenting
chiefly with cutaneous symptoms and with the potential
to negatively impact the overall health and quality of life
of patients.The immediate concern of most patients is likely to
be prompt resolution of the skin involvement...
Download PDF and Take the Test Online |
 Fall Clinical Dermatology 2007
An Update On Advance In Acne And Excerpts From What's New In The Medicine Cabinet
Download PDF |
 Acne Case Reports
Articles in this supplement are based on the proceedings from the 13th annual Acne Case Reports Roundtable Meeting.
Download PDF |
 2007 ADVANCES IN COSMETIC &
MEDICAL DERMATOLOGY
“MAUI DERM” CONFERENCE
ARTICLES IN THIS SUPPLEMENT ARE BASED ON SELECTED PRESENTATIONS
FROM THE ADVANCES IN COSMETIC & MEDICAL DERMATOLOGY
“MAUI DERM” 2007 CONFERENCE
HELD JANUARY 17-22, 2007, IN MAUI, HAWAII.
Download PDF |
 July 2007 CME Supplement
Nonmelanoma skin cancer (NMSC) is the most common malignancy, affecting
more than 1 million people in the United States alone.
Download PDF |
 2007 Winter Dermatology Conference Hawaii®
Based on selected presentations from the Winter Dermatology Conference® held in Kohala Coast, Hawaii, January 13-17, 2007.
Download PDF |
 2006 4th Annual Fall Conference Supplemental Proceedings
Articles in this supplement are based
on selected presentations from the
SDPA 4th Annual Fall CME Conference
held November 8-11, 2006, in San Diego, CA.
Download PDF |
|
|
|
|
|
|
|
About HMP Communications
HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications |
© 2008 HMP Communications | Contact Us
83 General Warren Blvd, Suite 100 | Malvern, PA 19355
|
|
